Log in
NASDAQ:ITCI

Intra-Cellular Therapies Stock Forecast, Price & News

$27.38
-1.03 (-3.63 %)
(As of 09/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$27.28
Now: $27.38
$28.52
50-Day Range
$17.61
MA: $22.10
$31.86
52-Week Range
$6.75
Now: $27.38
$43.56
Volume785,501 shs
Average Volume1.37 million shs
Market Capitalization$1.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.68
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases. It is also developing ITI-002 that inhibits the enzyme phosphodiesterase type 1; ITI-214 for Parkinson's disease; and ITI-333, for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. is headquartered in New York, New York.
Read More
Intra-Cellular Therapies logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.13 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ITCI
CUSIPN/A
Phone646-440-9333

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60,000.00
Price / Sales30,713.97
Book Value$3.52 per share

Profitability

Net Income$-147,720,000.00

Miscellaneous

Employees73
Market Cap$1.84 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$27.38
-1.03 (-3.63 %)
(As of 09/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for ITCI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

How has Intra-Cellular Therapies' stock price been impacted by Coronavirus?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ITCI stock has increased by 54.1% and is now trading at $27.38.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Intra-Cellular Therapies?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Intra-Cellular Therapies
.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Intra-Cellular Therapies
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its quarterly earnings results on Monday, August, 10th. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by $0.02. The biopharmaceutical company had revenue of $1.91 million for the quarter, compared to analysts' expectations of $3.05 million.
View Intra-Cellular Therapies' earnings history
.

What price target have analysts set for ITCI?

6 brokerages have issued 12 month price objectives for Intra-Cellular Therapies' shares. Their forecasts range from $26.00 to $80.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $53.33 in the next twelve months. This suggests a possible upside of 94.8% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies
.

Who are some of Intra-Cellular Therapies' key competitors?

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), AbbVie (ABBV), Clovis Oncology (CLVS) and Pfizer (PFE).

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:
  • Dr. Sharon Mates, Co-Founder, Chairman, CEO & Pres (Age 66)
  • Mr. Lawrence J. Hineline CPA, Sr. VP of Fin., CFO, Treasurer and Assistant Sec. (Age 63)
  • Dr. Robert E. Davis, Sr. VP & Chief Scientific Officer (Age 68)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel, Corp. Compliance Officer & Sec. (Age 46)
  • Dr. Andrew Satlin M.D., Exec. VP & Chief Medical Officer (Age 64)

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.67%), Vanguard Group Inc. (7.83%), Bellevue Group AG (5.62%), Wasatch Advisors Inc. (5.51%), Marshall Wace LLP (1.98%) and Nuveen Asset Management LLC (1.02%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates.
View institutional ownership trends for Intra-Cellular Therapies
.

Which major investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Alyeska Investment Group L.P., Hudson Bay Capital Management LP, Rhenman & Partners Asset Management AB, Atom Investors LP, UBS Group AG, Bank of America Corp DE, and TD Asset Management Inc.. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates.
View insider buying and selling activity for Intra-Cellular Therapies
.

Which major investors are buying Intra-Cellular Therapies stock?

ITCI stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Wasatch Advisors Inc., Marshall Wace LLP, Pinnacle Associates Ltd., Bailard Inc., Goldman Sachs Group Inc., Assenagon Asset Management S.A., and Nuveen Asset Management LLC.
View insider buying and selling activity for Intra-Cellular Therapies
.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $27.38.

How big of a company is Intra-Cellular Therapies?

Intra-Cellular Therapies has a market capitalization of $1.84 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]

This page was last updated on 9/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.